Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That makes $5.250.000 revenue accountable for the 2Q. 2019 results?
Hi Realfast95. I think that estimate of 0,47 for the 2Q is the best so far in historical terms.
Premarket is being done by junior trading. Excellent future for longs with the new acquisition.
Your suggestion that "surgeons study for the sake of it" leads me to another question. Who pays for the training of this specialists Vericel or they surgeons themselves?
And 3.000 patients divided by 900 surgeons makes 3,33 surgeries a year per surgeon. Too many cooks in the kitchen for me.
Iam of the opinion that Roche has to keep its law dpto. busy. They lost all demands.
So far so good for VERICEL but I am affraid time is ripe for downtrend.
Once we know the cost of a procedure, the % taken in each procedure and the number of surgeons. It is time to know the number of procedures executed during the last Q. Because estimate revenue is very poor vs the number of 800 surgeons. Is it probably that the market is not so large?
It seems your moving average of $12,40 has just fallen down as today´s low clocks $12,20. I wait for $11,20 to re-enter. There is not absolutely reason to have come down so sharply but manipulation is at large in VERICEL and we old know about and must play along with the band.
I think that VCEL. is catching up with HSGX share value wise. I hope I can buy them back well under $11 two weeks before results and then sell them again. Forget about making 100-200% profits in the short term any longer.
It seems the you aren´t going to sell many devices in Australia. All down as usual.
The company is valued as the same price as the shelve offering. Tomorrow is likely that shares will sink half price.
I told you to keep in the fast train( VCEL). VERICEL has at least 3 year´s time advantage to HSGX Which depends on a FDA nod to Neocart.In 3 yeas´s time MACI may develop in a techique even better tan MACI.
Realfast:I see without purpose spending $100 million in buying a product that has a disadvantage in time and scientific studies in comparison to IXYMCELL. OPK sales of over $1.5b would buy BCDA if interested.
Overpriced. Expecting a long deep fall.
I don´t know if I was cut off from the conference but I was quite
unimpressed it was a repeat of others conferences.
Gone past $14.00 towards first resistance on $14,15 mark.
Hi.Silver. Nice to see you back. Yes it´s been a great first Q. Taking into account that VERICEL had to pay back loans to the bank.For the inmediate future VERICEL will start hip and shoulder MACE operations to level up with europeans.
Don´t take the slow train that is Histogenix. Buy Vericel is 2 years ahead of HSGX with 2 products selling in the market and still very much undervalued.
Japanese interest has been express in the past. Vericel has a chinese partner for MACI,EPICEL and IXMCELL.
As far as I know the date for results has been not released yet.My estimate is about -10 which will be quite good.
At the conference was talked that VERICEL only takes 14% of the knee market so there is huge scope for improvement.The company has taken already strides in China through a chinese partner, there were plansto expand in Japan but I suppose the company on its own can´t cope with the enormous structure that a world-wide market will imply.A the moment international patients will have to undergo operations in USA.
Everlasting conference done by surgeons, Ceo, management and patients a mixture that reflects the self confidence of this company to be the leader in the world´s cell transpalantation.
New YouTube Vericel´s video "Maci implant from Vericel featured on NBC10 Boston news.
Thanks Luna. I suppose that MACI is not performed yet in the EU and they still perform the old fashion Carticel operation. I am thinking that in next conference for the 11th of May we are going to have some news about expansión in Europe.
Just a question for you gentlemen....We all know about MACI performance in the USA. What is the availability of MACI in other countries but the USA and China and what are the future projections of VERICEL internationally on MACI and EPICEL? Thank you.
04/04,just over an hour´s trade. 14% UP , Over half million shares traded . And We don´t know if there is any news to come into reason, or just someone very big entering at market prices.
Shorts camping in VERICEL at ease in just an hour they move PPS nearly $1 from $10,45 to $9,50.
Now going for new first support level at $9,20. If it is to follow current rhythm ít will reach it by the end of the day and the second support at $8,95 probably tomorrow.I can´t make a simil of Vcel. to current market trends. Vericel has its own "experiences".
Right now I think that VERICEL has done it again and shorts are doing a lot of money so they may lower the pps as they please.
PPS just lost the support at $9,65 and goes for $9,03 where it stands the 40 day moving average. So for the time being this is a brakeless run.
I expect a strong surge from now on It seems to me that shorts are about to become longs as 16% downturn from max. looks exagerated for a bright future that faces this company.
It seems going down towards $10.40 support.At this time of stillness technicals count a lot.
Luna, Thanks again.
Thanks Luna. I don´t understand that only $1m of ICT payment was accounted for in 4q.17 and what about the other $5m. Are they allowed to put them in 1q.18?
-0,13,EPS is the estimate for 1q 2018 I think this is the reason for the shares going back as we won´t have the benefit of the 6 million dollars chinese payment. Most likely we shall be back to ninish until 2q. 2018.Any thoughts about it?
He hinted some history about IXMYCELL but nothing new. So ladies and gentlemen I think we have to be contented with just MACI at the momento I am happy now but I think the company is nicely priced for the time being and don´t expect a further runaway.
Make yourself comfortable.
But the real bomb may come tomorrow at the Annual Connacord conference.
This article has been an amazing milestone Thanks "common`". In pre-market prices VCEL has touched $9.85. Watch out for results in 20 minutes.
Has this company any drugs in the market? If not who is funding? .How long before approval or filling. Thanks.